Home
/ 3sbio
/ Competitors

3sbio Competitors and Similar CompaniesClear all

3sbio's competitors and similar companies include BioNTech, Handa Pharmaceuticals, Orsenix and Ultimovacs.

	3sbio 3sbio (三生制药集团) is a company that develops biopharmaceuticals.	BioNTech BioNTech is biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.	Handa Pharmaceuticals Handa Pharmaceuticals is a company that develops and commercializes prescription medications.	Orsenix Orsenix is a clinical-stage biotech company focusing on oral therapies to treat cancer.	Ultimovacs Ultimovacs is a pharmaceutical company developing immunotherapies against cancer.
Founding Date	Founding Date 1993	Founding Date 2008	Founding Date 2005	Founding Date 2014	Founding Date 2011
Type	Type Public	Type Public	Type Subsidiary	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Shenyang, CN HQ	Locations Mainz, DE HQ Halle (Saale), DE Idar Oberstein, DE Marburg, DE Neuried, DE Planegg, DE Cambridge, US see more	Locations San Jose, US HQ	Locations HQ	Locations Oslo, NO HQ Uppsala, SE
Employees	Employees 5,3112% increase	Employees 5,500	Employees 6	Employees 6	Employees 19
Valuation ($)	Valuation ($) N/A	Valuation ($) 23.2 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 197.3 m
Employee Rating	Employee Rating 3	Employee Rating 3.3	Employee Rating N/A	Employee Rating N/A	Employee Rating N/A
Financial
Revenue (est.)	Revenue (est.) ¥6.9b (FY, 2022)	Revenue (est.) €17.3b (FY, 2022)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods ¥821.4m (FY, 2022)	Cost of goods €2.9b (FY, 2022)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ¥6.1b (FY, 2022)	Gross profit €14.5b (FY, 2022)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income ¥1.9b (FY, 2022)	Net income €9.4b (FY, 2022)	Net income N/A	Net income N/A	Net income (kr167.8m) (FY, 2022)
Funding
Total funding raised	Total funding raised $ 15.2m	Total funding raised $ 1.4b	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A